Key Takeaways
- Best-ever quarter, but margin optics masked the story: Revenue hit INR 851 crores with ~19% growth, yet CDMO margins dipped to 18.7% because Q4 FY25 had an unusually rich mix of late Phase 3 deliveries. The underlying margin trend is up 200 bps for the full year.
- The India pivot is now a live, multi-year unlock: A big pharma customer agreed to transfer the Swiss entity's largest molecule to India, and the group is pitching a single Switzerland-plus-India offering. Management expects India to help pull group operating margins back toward 35–40% over 3–5 years.
- Debt restructuring could be a material P&L tailwind: A plan to replace INR ~800 crores of 10.5–11% India debt with a foreign-currency loan at ~4% is underway, with a promoter ECB approved as the vehicle. Net interest cost is guided to not more than INR 100 crores for FY27.
- ADC and the French facility are the two swing factors: The Japanese innovator's ADC won first-line approval, and purchase orders are in hand. France is still losing EUR 9 million but is expected to halve that loss in FY27 and break even in FY28.
- What to watch next quarter: Whether management issues FY27 guidance after its self-imposed waiting period, any update on the India debt refinancing close, and the pace of new order conversion from the Sprint initiative and the combined drug-substance-drug-product offering.
The India Unlock
- First API tech transfer from Europe to India: The largest molecule produced out of the Swiss entity, for a big pharma customer, has been agreed for tech transfer. The move improves the group's cost position and lets it offer more attractive pricing.
- Margin arithmetic is compelling: Even after giving the customer a ~30% discount, the group-level margin on that product rises by 20–25%, per management. The transfer is phase-wise and will take a few years, but part of the project could move as an interim step by manufacturing additional intermediates.
- Single-offering pitch is gaining traction: A new senior BD organization jointly covers Carbogen Amcis (Switzerland) and Dishman (India), selling high-tech development plus large-scale manufacturing as one package. Management says positive effects are already visible and should convert to orders in coming years.
- India FY27 is already firmed up: Revenue and profitability will "definitely" increase over FY26. The FY28 top-line target is INR 500 crore-plus, backed by a pipeline of multiple projects and orders already received; management says that number is realistic even if the tech transfer moves slower than hoped.
- The 3–5 year ambition: India is the key strategy to lift group revenue and restore profitability to the historical 35–40% operating margin level that the India entity once delivered.
Harshil Dalal: "India is definitely, I would say, the growth in India is going to be one of the key strategies for us in order to increase the revenue at a group level, as well as improve the profitability significantly. Because historically, India had been doing close to about 35-40% operating margin for us. And that is kind of level that we would want to get back as quickly as possible."
Debt Restructuring & Interest Cost
- The plan: Replace India's high-cost rupee debt (INR ~800 crores at 10.5–11%) with a foreign-currency loan, likely in Swiss francs, at roughly 4%. A promoter entity will provide the ECB with a 10-year, unsecured tenure, freeing up securities currently pledged to Indian banks.
- Natural hedge logic: Because ~90% of India's revenue comes in foreign currency and the group has Swiss franc receivables and inflows, the foreign-currency debt acts as a hedge. The long tenure ensures foreign-currency revenue over the next decade will far exceed the debt.
- P&L impact: Consolidated net interest cost is guided to not more than INR 100 crores for FY27, with the India stand-alone portion not exceeding INR 70-odd crores. From Q2 or Q3, quarterly interest could drop to INR 30–35 crores or lower.
- Net debt reduction target: At least CHF 1–1.5 crores (roughly INR 150 crores) per year, with management calling that a minimum; all cash flow after maintenance CapEx and working capital goes to debt reduction.
- Refinancing timeline: Management expects conclusion around Q2 FY27. The goal is to get the India entity to net debt zero.
Harshil Dalal: "if my revenue was in rupees, and if my subsidiaries were also not generating any revenues in Swiss francs, and also at the India stand-alone level, then I'm with you. But here, I have a lot of Swiss franc receivables, a lot of Swiss franc inflows that are coming in, which will be utilized to service the interest and the principal payment."
ADC & High-Margin Growth Drivers
- Japanese innovator milestone: The partner received approval for its ADC as a first-line treatment, a significant step that expands the addressable patient population. Purchase orders for the linker/payload are in hand for the next years.
- Revenue visibility: The ADC linker/payload is expected to contribute CHF 3 crores in FY27 and CHF 4 crores in FY28, though the exact quarterly phasing depends on customer needs. The customer is co-investing in capacity, with the first co-investment complete and a second underway.
- Broader ADC pipeline: All Phase 3 molecules are progressing well, and more traction is coming from initiatives at the Swiss entity. The partnership with Celonic adds a combined MAb offering, from linker-payload synthesis through conjugation to drug product formulation, which management calls "very promising" with "a lot of attraction in the market."
- ADC share could keep rising: Management expects the ADC share of the business to increase, especially with the Celonic joint offering now in the market.
Harshil Dalal: "The partnership is very tight. We host them on our site regularly. We go there to see them and to discuss the progress of the project."
French Facility Turnaround
- Current drag: The French site generated EUR 8 million in revenue and a EUR 9 million EBITDA loss in FY26. ANSM approval was received about a year ago, and the facility is now bidding aggressively for Phase 3 projects and commercial supplies.
- FY27 path: Revenue is expected to rise to EUR 11–12 million, with losses halving to EUR 6 million. A new contract is already in hand, with validation batches being supplied now and higher quantities expected by end-FY27 or early FY28.
- FY28 target: Breakeven at the EBITDA level. The delay of two to four quarters versus earlier expectations reflects the time needed to convert the ANSM certification into actual customer wins.
- Strategic fix: The facility now offers drug substance (API) alongside drug product as a single package, which management says is already generating positive effects and should drive project flow to the drug product side.
CDMO Engine & Late-Phase Pipeline
- Q4 revenue was a record: INR 851 crores, with ~19% growth, driven by both CDMO (up 21%) and marketable molecules. The CDMO margin dip to 18.7% was a mix effect: Q4 FY25 had an unusually high share of late Phase 3 deliveries carrying the highest margins.
- Full-year margin expansion: EBITDA margins rose 200 bps to 19.3% for FY26. Marketable molecules margins jumped 940 bps to 18.8%, helped by strong Vitamin D analog demand and supplier diversification on wool grease that improved the cost base.
- Late-phase pipeline is deep: More than 10 late-phase projects are underway, including PPQ campaigns. Multiple sites are ready for FDA inspection and waiting for the agency to appear. The Sprint initiative to capture early-phase projects is attracting new clients across big pharma, midsized, and small pharma, which management calls important for the mid- and long-term future.
- Co-investments on track: Engineering activities in Switzerland for the partner-financed ADC expansion are proceeding according to plan, with 100% of CapEx financed by the partner. No other major CapEx is planned beyond maintenance and digital transformation (SAP, lab software, AI).
Stephan Fritschi: "we are well-positioned for the future and I'm absolutely optimistic and confident that we're on the right track and we get more products and business in."
Margin Bridge & Below-the-Line Items
- Q4 cost spike was partly one-off: Cost of revenue at ~15% was elevated because Q4 had more commercial supplies versus the Phase 3 development work that dominated the first nine months. Other expenses included a INR 30 crore swing from onerous contract provisions (a reversal in Q4 FY25 versus a fresh provision in Q4 FY26) and a one-off Swiss pension plan switch.
- Tax rate is elevated but has a downward path: The ~50% effective rate reflects losses in France, Shanghai, and India (goodwill depreciation) that cannot yet be offset against profits in Switzerland (taxed at ~15%) and the Netherlands (~25%). Management guides ~40% for FY27, ~30% for FY28, and ~15–20% in about three years as accumulated losses get utilized.
- Depreciation is stable in functional currency: No significant CapEx has been added; the last manufacturing line went live in France in Q4 FY25. INR-level depreciation fluctuates only with forex translation.
- Swiss franc sensitivity: A 5% movement in the franc affects only the EBITDA margin percentage (e.g., on a 20% margin), because most of the Swiss cost base is in francs while revenue is multi-currency.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Consolidated net interest cost | Not more than INR 100 crores | FY27 full year |
| India stand-alone interest cost | Not more than INR 70-odd crores | FY27 full year |
| Quarterly interest run-rate | INR 30–35 crores per quarter or lower | From Q2 or Q3 FY27 |
| India debt refinancing close | Replace INR ~800 cr high-cost debt with ~4% FX loan | Around Q2 FY27 |
| French facility revenue | EUR 11–12 million | FY27 |
| French facility EBITDA loss | EUR 6 million (down from EUR 9 million) | FY27 |
| French facility breakeven | EBITDA positive | FY28 |
| ADC linker/payload revenue | CHF 3 crores (FY27), CHF 4 crores (FY28) | FY27 / FY28 |
| Group EBITDA margin | 25% | FY28 |
| India top line | INR 500 crore-plus | FY28 |
| Effective tax rate | ~40% (FY27), ~30% (FY28), ~15–20% (~3 years) | FY27 / FY28 / FY29+ |
| Net debt reduction | At least CHF 1–1.5 crores (INR ~150 cr) per year | Annual, ongoing |
| Revenue CAGR | Close to ~15% | Next 3 years |
| CDMO / marketable molecules mix | 85% / 15% | Next 2–3 years |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | ₹851 cr, +19% YoY from ₹716 cr in Q4 FY25 |
| CDMO segment revenue | ₹690.8 cr, +21% YoY from ₹569 cr in Q4 FY25 |
| Marketable molecules segment revenue | ₹160.5 cr, +9.3% YoY from ₹146.9 cr in Q4 FY25 |
| EBITDA | ₹163 cr, 19.1% margin vs 23.9% in Q4 FY25 |
| CDMO segment EBITDA margin | 18.7%, vs 23.9% in Q4 FY25, due to lower share of late Phase 3 deliveries |
| Marketable molecules segment EBITDA margin | 21.1%, driven by higher Vitamin D analog share and supplier cost optimization |
| Profit after tax | ₹21.7 cr |
| Full-year FY26 revenue | ₹2,932 cr, +8% YoY from ₹2,711 cr in FY25 |
| Full-year FY26 EBITDA margin | 19.3%, +200 bps YoY from 17.3% in FY25 |
| Full-year FY26 profit after tax | ₹97.4 cr, vs ₹3.2 cr in FY25 |
| Full-year FY26 CDMO segment revenue | ₹2,441 cr, +6.5% YoY |
| Full-year FY26 marketable molecules segment revenue | ₹490.65 cr, +17% YoY from ₹418.5 cr in FY25 |
| Full-year FY26 marketable molecules EBITDA margin | 18.8%, +940 bps YoY |
| Net debt (excl. lease liabilities) | CHF 14.68 cr, down CHF 1.1 cr from CHF 15.76 cr at FY25 end |
| CapEx (full FY26) | CHF 2.24 cr |
| ADC contribution to CDMO revenue (FY26) | ~25% |
| French facility revenue (FY26) | €8 mn, with EBITDA loss of ~€9 mn; FY27 revenue expected €11-12 mn, loss ~€6 mn |
| India stand-alone debt | ~₹800 cr, average interest cost 10.5-11%; proposed ECB refinancing at ~4% to reduce interest cost |
| Effective tax rate guidance | ~40% for FY27, trending to ~30% in FY28 and 15-20% in ~3 years |
| Revenue CAGR target (next 3 years) | ~15% |
| EBITDA margin target | 25% by FY28 |